Do you want to read an article? Please log in or register.
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling
Multiple Myeloma (MM)
Related content
SPECIAL REPORT
Multiple Myeloma (MM)
Therapie des rezidivierten/refraktären Multiplen Myeloms
SPECIAL REPORT
Multiple Myeloma (MM)
Traitement du myélome multiple récidivant/réfractaire
Multiple Myeloma (MM)
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
J Clin Oncol
Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Gimsing P, Garderet L, Touzeau C, Buadi FK, Laubach JP, Cavo M, Darif M, Labotka R, Berg D, Moreau P
doi: 10.1200/JCO.21.00972
NINLARO® (Ixazomib) – der erste orale Proteasom-Inhibitor neu bei Multiplem Myelom in der Schweiz zugelassen
SPECIAL REPORT
Multiple Myeloma (MM)Further PublicationsCOVID-19
Treating MM-Patients During the COVID-19 Pandemic: An Interview with Prof. Maria-Victoria Mateos
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
SPECIAL REPORT
Multiple Myeloma (MM)
Patienten profitieren vom Proteasom-Inhibitor Ixazomib
NINLARO® (ixazomib), le premier inhibiteur du protéasome administré par voie orale, est désormais approuvé en Suisse pour le traitement du myélome multiple
RECOMMENDED
Multiple Myeloma (MM)
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
★ 2
Recommended by
Alexander Meisel, Faculty Member
J Clin Oncol.
Dimopoulos MA, Špička I, Quach H, Oriol A, Hájek R, Garg M, Beksac M, Bringhen S, Katodritou E, Chng WJ, Leleu X, Iida S, Mateos MV, Morgan G, Vorog A, Labotka R, Wang B, Palumbo A, Lonial S, TOURMALINE-MM4 study group.
doi: 10.1200/JCO.20.02060.Visit the full text of the original publication at ascopubs.org